CARCINOMA, NON-SMALL-CELL LUNG

This study is testing a new combination treatment for a serious complication where lung cancer spreads to the lining of the brain and spinal cord. It involves injecting a chemotherapy drug directly into the spinal fluid, alongside a targeted oral medication, for patients whose pr…

This is the first human trial of an experimental cancer drug called DM005. The study aims to find a safe and effective dose for patients with advanced solid tumors like lung and head/neck cancer that have stopped responding to standard treatments. Researchers will give the drug t…

This study is testing if a simple blood test can help doctors better treat advanced non-small cell lung cancer. The test looks for tiny bits of tumor DNA in the blood. Researchers want to see if this test can tell which patients will do well with immunotherapy alone and which mig…

This early-stage study is testing the safety and effects of an experimental cancer drug called PF-08046876 in adults with advanced solid tumors. The drug is an antibody drug conjugate designed to target and kill cancer cells. Researchers will give the drug through an IV to about …

This large study is testing various new drug combinations, including pembrolizumab with or without chemotherapy, for people with advanced non-small cell lung cancer. It will enroll over 1,000 participants across multiple smaller substudies, each focusing on different patient grou…

This study is testing an oral drug called BMS-986504 for people with advanced non-small cell lung cancer that has a specific genetic change called an MTAP deletion and has worsened after prior treatments. The main goals are to see if the drug is safe and if it can shrink tumors o…

This study is testing whether two different drug combinations can help control advanced lung cancer that has specific genetic changes. The trial will involve 480 people with advanced non-small cell lung cancer who have either never received treatment before or have tried one prev…

This global Phase 3 study is testing whether adding an experimental drug called LY3537982 (olomorasib) to standard cancer treatments works better than standard treatments alone for people with untreated advanced non-small cell lung cancer. The trial is specifically for patients w…

This study is testing if adding an investigational drug called LP-300 to standard chemotherapy helps people with advanced lung adenocarcinoma who have never smoked. The goal is to see if this combination can better control the cancer and help patients live longer after their init…

This study is monitoring the safety and effectiveness of the lung cancer drug brigatinib in real-world medical settings in South Korea. It will follow about 257 adults with ALK-positive advanced lung cancer who are starting brigatinib treatment for the first time. The main goal i…

This study is for adults with advanced non-small cell lung cancer that has worsened after two prior treatments, including immunotherapy and chemotherapy. It compares a new two-drug combination (THIO followed by cemiplimab) against standard chemotherapy. The goal is to see if the …

This is the first human trial of a new experimental cancer drug called LY4175408. It is designed to target and deliver a toxic payload specifically to cancer cells that have a certain marker (PTK7). The study will test the drug's safety, side effects, and early signs of effective…

This study is testing two new targeted cancer drugs against standard chemotherapy for people with advanced lung cancer that has spread and stopped responding to prior immunotherapy and chemotherapy. The goal is to see if these new drugs, which deliver treatment directly to cancer…

This study is testing whether adding two immunotherapy drugs to standard chemotherapy is safe and effective for treating advanced lung cancer in people who also have HIV. It will enroll 18 adults with stage IV non-small cell lung cancer and well-controlled HIV. The main goals are…

This study is testing whether adding a new drug called Sigvotatug Vedotin to standard immunotherapy works better for advanced non-small cell lung cancer. It will involve 714 people with high levels of a specific protein (PD-L1) in their cancer cells. Half will get the new combina…

This study follows 380 patients with advanced non-small cell lung cancer who have specific genetic mutations. Researchers will track how well patients do when receiving approved amivantamab-containing treatments in real-world clinical settings, not in controlled trials. The study…

This trial is testing if a combination of two drugs, already approved for a type of skin cancer, can help control other rare cancers that share the same genetic change (a BRAF V600 mutation). It aims to enroll 30 adult patients with various rare or uncommon cancers to see if the …

This study is testing if a new combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy helps people with advanced non-small cell lung cancer live longer than the current standard treatment (pembrolizumab plus chemotherapy). It is specifically for pa…

This study is testing the drug osimertinib as a first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The main goal is to understand how the cancer eventually becomes resistant to the drug. Participants wil…

This is a first-in-human study to test the safety and find the right dose of a new oral medicine, PF-07934040. It is being tested alone and in combination with other cancer drugs in people with advanced lung, colorectal, or pancreatic cancer that has a specific genetic change cal…

This study is testing an experimental pill called LY3537982 for people with advanced cancers that have a specific genetic change called KRAS G12C. The research aims to find the safest and most effective dose, both alone and combined with other cancer drugs, for patients with lung…

This study is testing whether adding a new oral drug called olomorasib to standard immunotherapy works better than immunotherapy alone for people with a specific genetic change (KRAS G12C) in their non-small cell lung cancer. It will enroll about 700 people whose cancer was remov…

This study is testing whether adding a personalized cancer vaccine called V940 to standard immunotherapy (pembrolizumab) after surgery helps keep lung cancer from coming back. It will enroll 680 people with non-small cell lung cancer whose tumors did not completely disappear with…

This study is testing whether adding a new gene therapy called Reqorsa to the standard drug osimertinib can help control advanced lung cancer that has started growing again. The trial is for adults with a specific genetic type of lung cancer (EGFR-mutant) whose cancer progressed …

This study is testing whether a new drug called BAT3306 works similarly to the established drug Keytruda in preventing lung cancer from returning after surgery. The trial will involve 140 adults with early-stage lung cancer who have had their tumors completely removed. Researcher…

This is a first-in-human study to test the safety and find the right dose of a new drug called PF-08046054/SGN-PDL1V for people with advanced solid tumors. It will be tested alone and in combination with another cancer drug, pembrolizumab. The study is recruiting 714 participants…

This study is testing a new drug, PF-08634404, when used alongside other cancer medicines in adults with advanced non-small cell lung cancer that has spread. The main goals are to see if the drug combinations are safe and if they can help control the cancer. The study is in early…

This study is testing a new drug called THIO, given before an immunotherapy drug (cemiplimab), for people with advanced non-small cell lung cancer. It is for patients whose cancer has continued to grow or returned after their first treatment that included an immunotherapy drug. T…

This study is testing whether adding a precise, high-dose radiation treatment (called CyberKnife) after standard chemotherapy and radiation helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It will involve 42 patients who have a…

This early-stage trial is testing the safety and dosing of an experimental drug called PF-08046050 in adults with advanced solid tumors that have returned or stopped responding to standard treatments. The drug is designed to attach to cancer cells and deliver a toxic payload dire…

This study is testing whether using a more focused, higher dose of proton radiation therapy can better control stage III non-small cell lung cancer while keeping severe side effects at an acceptable level. All 87 participants will receive this intensified proton treatment alongsi…

This large, late-stage study aims to see if a new immunotherapy drug called rilvegostomig works better than the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer. It will enroll about 830 participants worldwide who have not yet receive…

This study is testing whether a new drug called PF-08634404, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned…

This study is testing a new, easier-to-administer injection version of the drug amivantamab for people with advanced non-small cell lung cancer. It aims to see how well the injected drug shrinks tumors and how safe it is, either alone or combined with other treatments. The trial …

This early-stage trial is testing an experimental drug called sigvotatug vedotin for people with advanced solid tumors that have spread or cannot be removed by surgery. The study will first determine safe doses, then test the drug alone and in combination with other cancer medica…

This early-stage study is testing a new drug called JNJ-86974680 to find safe doses for people with advanced non-small cell lung cancer. Researchers will give the drug alone and combined with an immunotherapy drug and radiation therapy. The main goal is to check for side effects …

This study is following 800 people in China who have had surgery for a specific type of early-stage lung cancer. The goal is to see how well the drug alectinib works at keeping the cancer from coming back when taken after surgery. Researchers will track how long patients stay can…

This study is testing several new drug combinations for people with advanced lung cancer who haven't had any previous treatment. Researchers will give 450 participants different combinations of experimental drugs along with standard treatments to see which work best and are safes…

This study is testing whether adding a new targeted drug, adagrasib, to standard immunotherapy and chemotherapy works better for people with a specific type of advanced lung cancer. It will involve about 630 adults who have not yet received treatment for their advanced cancer and…

This is the first study in humans testing a new cancer drug called AZD9592. Researchers want to find safe doses and see if it helps control advanced cancers like lung, head/neck, and colorectal tumors. The study will test AZD9592 alone and combined with other cancer treatments in…

This study is testing which combination works better to shrink tumors before surgery for certain stages of non-small cell lung cancer. Before their operation, participants will receive either immunotherapy plus chemotherapy or immunotherapy plus targeted radiation. The goal is to…

This study is testing a new combination of two drugs, amivantamab and olomorasib, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find the safest and most effective dose of the drug pair and to see how…

This study is testing whether adding an experimental drug called JNJ-90301900 to standard chemotherapy and radiation treatment improves outcomes for people with advanced, inoperable lung cancer. The trial will involve 130 participants who will receive either the standard treatmen…

This is the first study in people to test a new targeted cancer drug called LY4170156. It aims to find a safe dose and see if it can help control advanced cancers, including ovarian, lung, breast, and pancreatic cancers. The study will also test the drug in combination with other…

This study is testing a new supportive care program called POISE for people with advanced lung cancer who are receiving targeted therapy. The program involves four visits with a specially trained palliative care clinician to help patients cope with uncertainty, build confidence i…

This study is testing whether a more intensive skin care plan can reduce severe rashes and nail problems in people with a specific type of advanced lung cancer. The 300 participants are starting treatment with two targeted drugs, amivantamab and lazertinib, which are known to cau…

This study aims to create a detailed national picture of lung cancer in Algeria by observing patients in their normal care. It will track about 3,750 adults with lung cancer across 21 hospitals to understand their diagnosis, treatments, and health outcomes. The goal is to gather …

This study is testing a new laboratory method to see if it can predict which cancer treatments will work best for a patient. Researchers will take a sample of a patient's tumor cells from a fluid or tissue biopsy and test how the cells react to different drugs in the lab. The goa…

This study aims to collect long-term health information and blood/tissue samples from 730 lung cancer patients treated at Nantes University Hospital. By tracking patients from diagnosis through their entire treatment journey, researchers hope to understand how treatments work in …